Related Experiment Video
Updated: May 24, 2025
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
CXCR4-A Potential Novel Theranostic Target in Adrenocortical Carcinoma
Abstract:
Adrenocortical carcinoma (ACC) is a highly aggressive malignancy with high recurrence rates and poor prognosis. There are only limited treatment options with poor response rates. ACCs are documented to express chemokine receptor CXCR4, which can be visualized using 68 Ga-pentixafor PET/CT. We herein present a case of ACC with local recurrence and peritoneal metastases, which was well visualized on FDG and pentixafor PET/CT. The high expression of CXCR4 offers the potential of theranostics and targeted endoradiotherapy in patients with metastatic ACC. We also observed thymic rebound to illustrate mild to moderate grade uptake of 68 Ga-pentixafor in this patient.
Insights
Adrenocortical carcinoma (ACC) shows high recurrence. Targeting chemokine receptor CXCR4 with 68 Ga-pentixafor PET/CT effectively visualized metastatic ACC, offering potential for theranostics and endoradiotherapy.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Adrenocortical carcinoma (ACC) is an aggressive cancer with limited therapeutic options.
- High recurrence rates and poor prognosis are characteristic of ACC.
- Chemokine receptor CXCR4 is expressed in ACC and can be targeted for imaging.
Purpose of the Study:
- To present a case of recurrent and metastatic ACC.
- To evaluate the utility of 68 Ga-pentixafor PET/CT for visualizing ACC.
- To explore the theranostic potential of CXCR4-targeting agents in ACC.
Main Methods:
- Case presentation of ACC with local recurrence and peritoneal metastases.
- Diagnostic imaging using 18F-FDG PET/CT and 68 Ga-pentixafor PET/CT.
- Assessment of CXCR4 expression and its correlation with imaging findings.
Main Results:
- 68 Ga-pentixafor PET/CT successfully visualized local recurrence and peritoneal metastases in ACC.
- FDG PET/CT also contributed to the visualization of the disease.
- Observed thymic rebound with mild to moderate 68 Ga-pentixafor uptake.
Conclusions:
- High CXCR4 expression in metastatic ACC is confirmed.
- 68 Ga-pentixafor PET/CT is a valuable tool for diagnosing and staging ACC.
- Targeting CXCR4 presents a promising theranostic and endoradiotherapy approach for ACC.
More Related Videos
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
05:21Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
Published on: September 13, 2024
